Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

4344 - Phase 1 Trial of CV301 in Combination with Anti-PD-1 Therapy in Non-squamous NSCLC


30 Sep 2019


Poster Display session 3



Tumour Site

Non-Small Cell Lung Cancer


Arun Rajan


Annals of Oncology (2019) 30 (suppl_5): v475-v532. 10.1093/annonc/mdz253


A. Rajan1, J.E. Gray2, S. Devarakonda3, J. Gurtler4, R. Birhiray5, E. Paschold6, A. Dasgupta7, C. Heery8, C. Pico-Navarro9, M. Piechatzek10, E. Wagner11, E. Menius12, R.N. Donahue13, J. Schlom14, J.L. Gulley15

Author affiliations

  • 1 Thoracic And Gi Malignancies Branch, National Cancer Institute, 20892 - Bethesda, MD/US
  • 2 Thoracic Medical Oncology, H. Lee Moffitt Cancer Center University of South Florida, 33612 - Tampa/US
  • 3 Division Medical Oncology, Washington University School of Medicine, 63110 - St. Louis/US
  • 4 Medical Oncology, Community Practice, 70006 - Metaire, LA/US
  • 5 Medical Oncology, Investigative Clinical Research of Indiana, 46260 - Indianapolis, IN/US
  • 6 Medical Oncology, Forsyth Memorial Hospital, 27103 - Winston-Salem, NC/US
  • 7 Medical Oncology, Millennium Oncology, 77090 - Houston, TX/US
  • 8 Clinical Development, Bavarian Nordic, 27560 - Morrisville/US
  • 9 Clinical Development, Bavarian Nordic Inc, 27560 - Morrisville/US
  • 10 Clinical Development, Bavarian Nordic GmbH, 82152 - Munich/DE
  • 11 Clinical Development, Bavarian Nordic GmbH, 82152 - Martinsried (Planegg)/DE
  • 12 Biometrics, Bavarian Nordic Inc, 27560 - Morrisville, NC/US
  • 13 Laboratory Of Tumor Immunology And Biology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH),, 20892 - Bethesda/US
  • 14 Laboratory Of Tumor Immunology And Biology, Center for Cancer Research, National Cancer Institute, 20892 - Bethesda/US
  • 15 Genitourinary Malignancies Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH),, 20892 - Bethesda/US


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4344


CV301 is an MVA-based vaccine encoding human transgenes MUC1, CEA and TRICOM. A phase I dose-escalation trial (Gatti-Mays E, et al. CCR 2019) concluded that CV301 is safe in advanced cancer patients and generated specific T cell responses against the encoded antigens. Preclinical data supports the rational for combining CV301 with PD-1 inhibitors. The primary objective of this trial was to evaluate safety and tolerability of this combination.


Patients with advanced non-squamous-NSCLC without actionable alterations in EGFR, ALK and ROS1 were eligible. Two priming doses of MVA-BN-CV301 (MVA) were administered in 4 separate subcutaneous (SC) injections of 4x10^8 IU, 4 weeks apart, followed by boosting doses of Fowlpox-CV301 (FPV) given as a single injection of 1x10^9 IU SC q2w for weeks 9-15, q4w for weeks 19-51 and q13w up to 17 doses for Cohort 1 (C1), q3w for weeks 7-22, q6w for weeks 28-52 and q12w up to 15 doses for Cohort 2 (C2). C1 included patients pre-treated with platinum-containing chemotherapy, who were considered eligible for nivolumab (N; 240 mg IV q2w). C2 included patients receiving frontline treatment with pembrolizumab (P; 200 mg IV q3w) after a minimum of 11 weeks of SD per RECIST.


Between Oct-2017 and Sep-2018, 12 pts were recruited, 4 in C1 and 8 in C2. Median age was 64, and 9 pts were F. Majority of patients were former-smokers (9, 1 current, 2 never). As of Mar-2019 data cut-off, mean treatment duration was 272 days in C1 and 193 days in C2, with 7 pts continuing and 5 discontinuing treatment. Both doses of MVA were administered to 3/4 pts in C1 and 7/8 pts in C2. Median FPV doses/pt: C1=12 and C2=6. CV301 injection-site reactions and flu-like symptoms were observed in all C1 and 7/8 C2 pts. CTCAE ≥ grade 3 AEs were observed in 3/4 C1 and 3/8 C2 pts with 1 fatal TEAE. IRAEs included 1 autoimmune hepatitis, and 1 pneumonitis fulfilling criteria of DLT. As of data-cut, we observed 1 CR (C1), 10 SD, and 1 discontinuation prior to first scheduled RECIST assessment.


The treatment of NSCLC with CV301 + N or P is feasible and tolerated, with no observed increase in the frequency or severity of expected AEs or IRAEs for each component of the combination.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Bavarian Nordic Inc.


Bavarian Nordic Inc.


C. Heery: Honoraria (self), Leadership role: Bavarian Nordic. C. Pico-Navarro: Honoraria (self): Bavarian Nordic. M. Piechatzek: Full / Part-time employment: Bavarian Nordic. E. Wagner: Full / Part-time employment: Bavarian Nordic. E. Menius: Full / Part-time employment: Bavarian Nordic. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.